What Is Nesiritide Used For? Approved Uses, Per the Label

Nesiritide is a prescription medicine given intravenously in hospital settings. It is a recombinant form of human B-type natriuretic peptide (BNP), sold under the brand name Natrecor, and published descriptions of its United States prescribing information list one approved indication in acute heart failure. This page summarises what the literature reports about that indication, the trials behind it, and the regulatory history that followed. This page is for educational purposes only and is not medical advice; consult a licensed physician about any question regarding treatment, suitability or administration. No dosing information appears here.

What nesiritide is, in pharmacological terms

Nesiritide belongs to the natriuretic peptide family. A pharmacology review of natriuretic peptide structures, receptors and physiologic functions described how BNP acts through natriuretic peptide receptor A to raise intracellular cyclic GMP, producing vasodilation, natriuresis and suppression of neurohormonal activation, and it discussed recombinant natriuretic peptides as therapeutic applications of that biology (PMID 19089336). A translational review of BNP in heart failure covered preclinical and clinical trial data for the peptide and for recombinant human BNP preparations used intravenously in decompensated patients (PMID 25771949). For broader background on the molecule itself, see the nesiritide overview.

The approved indication, as worded in the label

Published accounts of the Natrecor prescribing information describe a single labeled use: the intravenous treatment of patients with acutely decompensated heart failure who have dyspnea at rest or with minimal activity. A health policy analysis of the product traced that indication from approval through the marketing and safety debate that followed (PMID 16835191). A clinical review of efficacy and safety in acute decompensated heart failure described the same inpatient intravenous setting as the context in which the agent was studied and marketed (PMID 20136602). The cited sources do not state a specific label revision year, so no revision date is asserted here; the current prescribing information held by the manufacturer is the authoritative wording.

Trial evidence behind the indication

Hemodynamic and symptom endpoints

The clinical case for the approved indication rested on randomized comparisons in acutely decompensated heart failure. A 2010 review of efficacy and safety reported that nesiritide improved hemodynamic measures and dyspnea in acute decompensated heart failure trials, while also summarising the controversy that developed around renal function and mortality signals in pooled analyses (PMID 20136602). A German-language review of natriuretic peptides in the therapy of acute decompensated heart failure placed nesiritide among intravenous vasodilator strategies evaluated for symptom relief in that setting (PMID 21877307).

ASCEND-HF and the large outcome programme

The best known large randomized evaluation of nesiritide in acute heart failure was ASCEND-HF. A substudy of that trial examined interleukin-6 concentrations in acute heart failure patients and reported that higher interleukin-6 levels were associated with worse clinical outcomes in the enrolled population (PMID 33497809). The existence of a trial of that scale is itself part of the regulatory story: the drug was approved on symptom and hemodynamic grounds, and researchers later ran a dedicated outcome trial to address questions raised after marketing (PMID 16835191).

Mechanistic and biomarker comparisons

An exploratory study in acute decompensated heart failure compared intravenous nitroglycerin and nesiritide and reported differences in novel cardiorenal and inflammatory biomarkers between the two vasodilator strategies (PMID 21576282). Work of that kind supports mechanism discussions rather than creating any new labeled indication, and the authors framed the analysis as exploratory (PMID 21576282).

Regulatory history of the indication

A health policy analysis titled "The rise and fall of Natrecor for congestive heart failure" described the product's United States approval in 2001 for acutely decompensated heart failure, its rapid commercial uptake, the emergence of published concerns about renal effects and mortality, and the implications of that sequence for drug policy and post-marketing oversight (PMID 16835191). The 2010 efficacy and safety review described how those concerns reframed clinical use and prompted further randomized evaluation before guideline positioning settled (PMID 20136602).

Two points matter for anyone reading the label today. First, the approved indication has remained anchored to the acute inpatient setting described in those sources (PMID 20136602). Second, the natriuretic peptide concept itself continued in a different pharmacologic direction: a review of angiotensin receptor-neprilysin inhibitors described how blocking neprilysin raises endogenous natriuretic peptide levels and how that approach was developed for chronic heart failure management (PMID 26082640). That is a separate class of medicines with its own labeling, not an extension of the nesiritide indication.

Safety findings in nesiritide trials: What Studies Report

Adverse event reporting for nesiritide centres on its vasodilator pharmacology. The 2010 review reported that hypotension was the principal dose-related adverse effect observed with intravenous nesiritide in acute decompensated heart failure trials, and it discussed the debate over whether treatment worsened renal function or affected mortality in pooled analyses (PMID 20136602). The health policy analysis described how published signals regarding renal function and mortality drove expert review and changed prescribing patterns after launch (PMID 16835191).

A meta-analysis of nesiritide in patients with acute myocardial infarction and heart failure pooled randomized data and reported on efficacy and safety outcomes in that specific combined population (PMID 31948318). A study of safety and efficacy in pediatric heart failure reported on tolerability in children treated for decompensation (PMID 17826644). Neither of those bodies of evidence establishes a labeled use on its own; both are described here as published research. Only a prescribing clinician with access to the full prescribing information and the individual clinical picture can judge whether any of this applies to a particular patient.

Settings studied in research that are not approved indications

One short factual note belongs here. Pediatric heart failure (PMID 17826644) and acute myocardial infarction complicated by heart failure (PMID 31948318) have been studied, and intravenous vasodilators are discussed within broader frameworks of acute circulatory failure and shock pathophysiology (PMID 30543176), but these are investigational or off-label contexts in the published literature and are not approved indications on the United States label described by the cited sources (PMID 16835191).

How the approved use is framed in practice

• Acute, not chronic. The labeled indication describes acutely decompensated heart failure with dyspnea at rest or with minimal activity, a hospital setting rather than ongoing outpatient therapy (PMID 16835191).
• Symptom and hemodynamic basis. Reviews reported dyspnea and hemodynamic endpoints as the evidence base supporting that indication (PMID 20136602).
• Outcome data came later. A large randomized trial programme, ASCEND-HF, generated the outcome and biomarker datasets analysed in subsequent publications (PMID 33497809).
• Mechanism is receptor mediated. Natriuretic peptide receptor A signalling through cyclic GMP underlies the vasodilatory and natriuretic effects described in pharmacology reviews (PMID 19089336).

Questions that belong with a prescribing clinician

Whether nesiritide is appropriate for a specific person, how it compares with other intravenous therapies for acute decompensation, and how monitoring is handled are clinical decisions. Published reviews describe the trade-offs at a population level (PMID 21877307), but they do not substitute for the prescribing information or for a clinician's assessment. Any individual use question should be directed to a licensed physician or the treating hospital team.

References

• The rise and fall of Natrecor for congestive heart failure: implications for drug policy (Health Affairs, 2006)
• Efficacy and safety of nesiritide in patients with acute decompensated heart failure (Expert Review of Cardiovascular Therapy, 2010)
• Natriuretic peptides: their structures, receptors, physiologic functions and therapeutic applications (Handbook of Experimental Pharmacology, 2009)
• BNP and Heart Failure: Preclinical and Clinical Trial Data (Journal of Cardiovascular Translational Research, 2015)
• Interleukin-6 and Outcomes in Acute Heart Failure: An ASCEND-HF Substudy (Journal of Cardiac Failure, 2021)
• Modulation of novel cardiorenal and inflammatory biomarkers by intravenous nitroglycerin and nesiritide in acute decompensated heart failure: an exploratory study (Circulation: Heart Failure, 2011)
• Nesiritide in patients with acute myocardial infarction and heart failure: a meta-analysis (Journal of International Medical Research, 2020)
• Safety and efficacy of nesiritide in pediatric heart failure (Journal of Cardiac Failure, 2007)
• Natriuretic peptides in the therapy of acute decompensated heart failure (Deutsche Medizinische Wochenschrift, 2011)
• Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond (Vascular Health and Risk Management, 2015)
• Shock: Classification and Pathophysiological Principles of Therapeutics (Current Cardiology Reviews, 2019)